The Technical Analyst
iShares Genomics [IDNA]
Exchange: NYSE
iShares Genomics Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.88% $23.47
America/New_York / 8 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 129.74 mill |
| EPS: | 10.25 |
| P/E: | 2.29 |
| Earnings Date: | N/A |
| SharesOutstanding: | 5.53 mill |
| Avg Daily Volume: | 0.0350 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.10x |
| Company: PE 2.29 | sector: PE 23.85 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.17x |
| Company: PE 2.29 | industry: PE 13.52 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 23.08 - 23.86 ( +/- 1.67%) |
| ATR Model: 14 days |
Forecast:
16:00 - $23.47
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $23.47
Forecast 2: 16:00 - $23.47
Forecast 3: 16:00 - $23.47
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $23.47 (-1.88% ) |
| Volume | 0.0216 mill |
| Avg. Vol. | 0.0350 mill |
| % of Avg. Vol | 61.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IDNA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IDNA
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
Latest News
2024-02-18 06:39:11 - Seeking Alpha
IDNA: Healthcare Dashboard For February
This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheaper than their peers in February.
2023-11-17 16:04:49 - ETF Trends
VettaFi Voices On: Accessing Disruptive Innovation
Good Morning, VettaFi Voices! Disruptive innovation is a popular topic, and it encompasses everything from bitcoin and cryptocurrency to electric vehicles to artificial intelligence.
2023-06-08 04:03:29 - Seeking Alpha
IDNA: Continues To Underperform, But With Long-Term Potential
I rate IDNA a Hold due to its focus on biotech stocks with long-term growth potential in a rapidly growing healthcare industry. Despite impressive growth since its inception in 2019, IDNA has experienced a downward trajectory since 2021, with its current price lower than at inception. The healthcare industry is predicted to be the fastest growing industry in the US in 2023, with a 15% growth rate expected by 2027, making it a profitable long-term investment space.
2023-06-07 12:34:24 - Seeking Alpha
IDNA: Thematic Biotechnology Index Fund Only Suitable For The Long Run
Genomic revolution and pharmacogenomics have strong growth prospects that may enable the iShares Genomics Immunology and Healthcare ETF biotech portfolio to generate supernormal growth. In order to enable retail investors to benefit from this technological advancement in the field of DNA, investors can think of options like IDNA. Since its creation, IDNA's price has more than doubled within a span of almost 39 months. However, since September 2022, price has been in a steady decline.
2023-04-10 10:01:21 - ETF Trends
Thematic Index Lineup Joins VettaFi and the Future Is Bright
A decade ago, when the ROBO Global Robotics & Automation Index ETF (ROBO) launched, the U.S. thematic ETF market was nascent, with only a handful of products and minimal assets. However, at the end of 2021, there was approximately $130 billion in assets invested, per Global X.
2023-03-15 11:31:39 - InvestorPlace
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.
2023-02-16 15:45:22 - Seeking Alpha
IDNA: Healthcare Dashboard For February
Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality.
2023-01-24 09:02:08 - Zacks Investment Research
Will 2023 be the Year of Cathie Wood ETFs?
Cathie Wood, famous for the success of Ark Investment???s winning products, had faced a miserable fate in 2022.
2023-01-11 18:09:00 - Seeking Alpha
Can Health Care Stocks Outperform Again In 2023?
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
2022-11-16 12:26:02 - Seeking Alpha
IDNA: Healthcare Dashboard For November
The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Healthcare equipment and life science tools are overvalued by about 25% regarding the same metrics.